Quick Answer
MiNK Therapeutics, Inc. reported Stockholders Equity of -$14.23 million for the year ending 2025.
- MiNK Therapeutics, Inc. showed an increase of +27.4% in Stockholders Equity from 2024 to 2025.
- This data is from MiNK Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$40.06 million | Q2 2020: -$44.50 million | Q3 2020: -$51.34 million | Q1 2021: -$57.08 million | Q2 2021: -$63.18 million | Q3 2021: -$76.51 million | Q1 2022: $17.31 million | Q2 2022: $13.69 million | Q3 2022: $6.76 million | Q1 2023: -$4.48 million | Q2 2023: -$9.50 million | Q3 2023: -$13.58 million | Q1 2024: -$20.30 million | Q2 2024: -$16.58 million | Q3 2024: -$17.55 million | Q1 2025: -$21.79 million | Q2 2025: -$25.19 million | Q3 2025: -$13.51 million.
- Over the full 7 years of available data (2019 to 2025), MiNK Therapeutics, Inc.'s Stockholders Equity has grown by 60.8%.
- Historical annual values: Fiscal year 2025: -$14.23 million | Fiscal year 2024: -$19.59 million | Fiscal year 2023: -$18.06 million | Fiscal year 2022: -$401.3 thousand | Fiscal year 2021: $23.78 million | Fiscal year 2020: -$53.87 million | Fiscal year 2019: -$36.33 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: